Scinopharm TaiwanTPE:1789 +2.50%76 Interest Coverage is 3.55 as of Dec. 2025, which is 85% below its 10-year median of 24.40. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 684 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 52.92% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Scinopharm Taiwan's
Operating Income
for the
three
months ended in Dec. 2025 was NT$10 Mil. Scinopharm Taiwan's Interest Expense for the
three
months ended in Dec. 2025 was NT$-3 Mil.
Scinopharm Taiwan's interest coverage for the quarter that ended in Dec. 2025 was 3.55.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Scinopharm Taiwan's Interest Coverage or its related term are showing as below:
TPE:1789'
s Interest Coverage Range Over the Past 10 Years
Min: 4.8 Med: 24.4 Max: 51.26
Current: 11.03
TPE:1789's Interest Coverage is ranked worse than 52.92% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs TPE:1789: 11.03
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Scinopharm Taiwan Interest Coverage Related Terms
Scinopharm Taiwan Interest Coverage Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TPE:1789 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Interest Coverage of 3.55 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Scinopharm Taiwan and its competitors. This is 85% below median its historical median of 24.40. Over the past decade, Scinopharm Taiwan's Interest Coverage has ranged from 4.80 to 51.26. According to the industry distribution chart, Scinopharm Taiwan ranks #362 out of 684 companies in the Drug Manufacturers industry, placing it in the top 52.9%.
Is Scinopharm Taiwan's Interest Coverage too high?
Scinopharm Taiwan's current Interest Coverage of 3.55 is 85% below median its 10-year median of 24.40. Over the past 10 years, this metric has ranged from a low of 4.80 to a high of 51.26. The Drug Manufacturers industry median Interest Coverage is 12.77. Scinopharm Taiwan's value of 3.55 is 72.2% below this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #362 out of 684 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #362 out of 684 companies for Interest Coverage. This places Scinopharm Taiwan in the lower half of its industry. The industry median Interest Coverage is 12.77. Scinopharm Taiwan's value of 3.55 is 72.2% below this benchmark. Historically, Scinopharm Taiwan's own Interest Coverage has ranged from 4.80 to 51.26 over the past decade. While the company's 10-year median is 24.40 vs. the industry median of 12.77, Scinopharm Taiwan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current Interest Coverage of 3.55 is 72.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Interest Coverage is 3.55, which is 85% below median its own 10-year median of 24.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.50 — trading 24.1% below its estimated fair value. The current Interest Coverage is 3.55, which is 85% below median its 10-year median of 24.40 and 72.2% below the Drug Manufacturers industry median of 12.77. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Interest Coverage is 3.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.50 is trading 24.1% below its estimated GF Value™ of NT$27.02.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Interest Coverage: 3.55 (85% below median its 10-year median of 24.40)
GF Value™: NT$27.02 vs. price of NT$20.50 (24.1% below fair value)
Industry Position: 72.2% below the Drug Manufacturers median (#362 of 684)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
